Literature DB >> 17242448

Nonalcoholic Fatty liver disease and obesity.

Sherif Saadeh1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized medical condition that may progress to hepatic cirrhosis with liver failure. The pathologic picture resembles that of alcohol-induced liver injury, but it occurs in patients who do not abuse alcohol. NAFLD is more common among patients with evidence of insulin resistance. NAFLD refers to a wide spectrum of liver damage, ranging from simple steatosis to steatohepatitis, fibrosis, and cirrhosis. The clinical implications of NAFLD are derived mostly from its common occurrence in the general population, specifically in obese individuals, and its potential to progress to cirrhosis and liver failure. It is difficult to propose a treatment strategy for NAFLD because its pathogenesis is poorly understood; however, the most commonly associated clinical features of obesity, diabetes mellitus, lipid disorders, and hypertension deserve therapeutic interventions independent of NAFLD. It is also not known if and how treatment of these other conditions affects the natural history of NAFLD, particularly in the long term.

Entities:  

Mesh:

Year:  2007        PMID: 17242448     DOI: 10.1177/011542650702200101

Source DB:  PubMed          Journal:  Nutr Clin Pract        ISSN: 0884-5336            Impact factor:   3.080


  22 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Selection of reference genes for qRT-PCR in high fat diet-induced hepatic steatosis mice model.

Authors:  Lingyan Xu; Xinran Ma; Bin Cui; Xiaoying Li; Guang Ning; Shu Wang
Journal:  Mol Biotechnol       Date:  2011-07       Impact factor: 2.695

3.  Quantification of lipid droplets and associated proteins in cellular models of obesity via high-content/high-throughput microscopy and automated image analysis.

Authors:  Patrick M McDonough; Ramses M Agustin; Randall S Ingermanson; Patricia A Loy; Benjamin M Buehrer; James B Nicoll; Natalie L Prigozhina; Ivana Mikic; Jeffrey H Price
Journal:  Assay Drug Dev Technol       Date:  2009-10       Impact factor: 1.738

4.  Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse.

Authors:  Soumen K Manna; Andrew D Patterson; Qian Yang; Kristopher W Krausz; Henghong Li; Jeffrey R Idle; Albert J Fornace; Frank J Gonzalez
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

5.  Qushi Huayu Decoction (祛湿化瘀方) inhibits protein and gene expression of cathepsin B in HepG2 cells induced by free fatty acids.

Authors:  Qin Feng; Yang Cheng; Yi-yang Hu; Hui Zhang; Jing-hua Peng; Ning Zhang
Journal:  Chin J Integr Med       Date:  2010-11-26       Impact factor: 1.978

6.  A role for Sp1 in transcriptional regulation of phosphatidylethanolamine N-methyltransferase in liver and 3T3-L1 adipocytes.

Authors:  Laura K Cole; Dennis E Vance
Journal:  J Biol Chem       Date:  2010-02-11       Impact factor: 5.157

7.  Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease.

Authors:  Zhou-wen Chen; Li-ying Chen; Hong-lei Dai; Jian-hua Chen; Li-zheng Fang
Journal:  J Zhejiang Univ Sci B       Date:  2008-08       Impact factor: 3.066

Review 8.  Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease.

Authors:  Vikas Khullar; Angela Dolganiuc; Roberto J Firpi
Journal:  World J Transplant       Date:  2014-06-24

Review 9.  Effect of obesity on the pharmacokinetics of drugs in humans.

Authors:  Michael J Hanley; Darrell R Abernethy; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

10.  Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients.

Authors:  Anna Katharine Hindle; Claire Edwards; Alisha Mendonsa; Marcos Rojkind; Tim McCaffrey; Sidney Fu; Fred Brody
Journal:  Surg Endosc       Date:  2009-12-30       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.